Kornimate/medical-research-clean huggingface dataset:
the achilles tendon length measure (atlm) - development and validation

Conditions: Achilles Tendon Rupture

Summary: the purpose of this study is 1) to develop and validate a new measurement to assess the length of the achilles tendon after rupture, and 2) to examine if goniometer measurement of the ankle joint is a better method.

it has been shown that an achilles tendon elongation compared to the un-injured leg is negatively associated with the clinical outcome and strength of the gastrocnemius muscle. despite this knowledge, there is a lack of a valid score system that can measure the length of the achilles tendon in daily clinical practice. patients, who follow a rehabilitation program at the department of physiotherapy, also have their achilles tendon examined for lengthening by physiotherapists, to evaluate if the heeling progresses as planned. of concern, this examination is based on measures, which have not been thoroughly validated. the atlm test use the same test position of the lower limb as being used in matles test. besides observing the foot's position, we will measure the distance from a point of reference on the foot to the examination coach. reproducibility and responsiveness of the atlm will be examined, while concurrent validity will be examined against ultrasound and a goniometry measure. the ultrasound is considered the most precise, secure and objective measure. the atlm and goniometer measures will be conducted at 8 and 16 weeks after the injury. at 8 weeks there will be two physiotherapists conducting these measures (to investigate inter-tester reliability). the ruler and goniometer will have the numbers hidden. a third physiotherapist will read the results at 8 and 16 weeks, so that the physiotherapists will be blinded towards the results. a person blinded to these results will conduct the ultrasound.

Eligibility criteria:
inclusion criteria: * patients aged 18-60. * patients who are being referred to the rehabilitation program for patients with an aatr, at hvidovre hospital. * the patients have to speak and understand danish. * the patients have to be able to sign the written informed consent. exclusion criteria: * patients who earlier have had a rupture of one or both at. * patients who have had an operation one of the achilles tendons before. * patients who have been diagnosed with arterial insufficiency in legs. * patients with a terminal disease or who suffers from a critical medical illness. * patients where the distance from rupture to calcaneus is less than 1 cm (examined by palpation or in doubt, measured with an ultrasound) * fluoroquinolone treatment within the last 6 months. * tendinosis treated with corticosteroids (tablets or injections) within the last 6 months.

Keywords: achilles tendon rupture, lengthening, validity, goniometer.
cross sectional cfar hiv/covid-19 study

Conditions: SARS-CoV Infection; Covid19

Summary: the main purpose of this research study is to learn the rate of sars cov-2 on hiv infected children, adolescents, and youth receiving their primary hiv care at the university of miami miller school of medicine.


Eligibility criteria:
inclusion criteria: * being a patient to the pediatric or adolescent clinic located at batchelor children research institute (bcri) * being diagnosed with hiv infection by the time of enrollment * at enrollment, 3 to \< 26 years exclusion criteria: * patient will be excluded from the study if any of the following are identified: * patients under legal age and in the state's custody * participant or legal guardian unable to sign informed consent forms * participant unable to complete study visits

Keywords: hiv
multi-modal quantitative imaging of the skin

Conditions: Skin Cancer; Skin Diseases; Atopic Dermatitis; Psoriasis; Raynaud Disease; Diabetic Foot; Peripheral Arterial Disease

Summary: this clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.

this clinical investigation aims to evaluate the feasibility of full-body multi-modal imaging for screening, monitoring and diagnostic support purposes in primary care, by assessing accuracy of body measurements and sensitivity and correlation to disease. the performance in detection of skin cancer, peripheral arterial disease, raynaud's phenomenon and dermatological conditions are within the scope of this investigation. the multi-modal technology is based on camera systems, which can capture high-resolution 2d and 3d color images (visible spectrum) and thermal images (infrared spectrum). the appearance, shape, color, etc. and topography of lesions is captured by the color 2d camera of the system and can thus be inspected / quantified. thermal images are used to capture thermal gradients which may be indicative of microcirculatory changes. the 3d camera is used to ensure that 2d color data and thermal data can be geometrically aligned, thus being able to compare characteristics of the two data types from the very same skin segment / lesion. furthermore, it enables geometrical measurements of the lesions. the participants mainly consist of a prospective primary care population, that undergo an investigation at a primary care visit. full-body images (front and back) of all participants are captured during the visit. participants receive a questionnaire to fill in on-site, where they state whether they have/have had any of the diseases and conditions part of the investigation. in some subjects, body measurements (circumference and distance) will be acquired manually as part of the primary care flow. repeated yearly measurements may be performed in subjects who are interested.

Eligibility criteria:
inclusion criteria: * adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation. * patients with signed informed consent exclusion criteria: * cognitive impairment * patients unable to understand the oral and written study information in swedish or english * other severe disorder or terminal disease * patients unable to provide an informed consent * patients not able to keep balance, while standing up with closed eyes, without any aid * claustrophobic patients
risk reduction intervention for vulnerable young adult males

Conditions: Sex; Substance Use; HIV

Summary: the primary aim of this study is to test a brief 4-session risk reduction intervention, based on motivational enhancement therapy (met) to reduce the co-occurrence of club drug use and sexual risk taking behaviors among non-treatment seeking young men who have sex with men (ymsm) in nyc.

this study is a randomized clinical trial. a sample of 300 non-treatment seeking ymsm (ages 18-24) who report risky sex and club drug use in the past 90 days are being enrolled using active and passive community-based recruitment strategies in nyc. after baseline assessment, participants are being randomly assigned to one of two study arms: a brief risk reduction intervention condition - a four session met intervention piloted for feasibility and acceptability among ymsm, designed to increase readiness to change club drug use and unprotected sex; or an education comparison condition - four sessions of facilitated education regarding the effects of club drugs and unprotected sex. participants undergo follow-up assessments 3, 6, 9, and 12 months after baseline.

Eligibility criteria:
inclusion criteria: * at least 5 days of drug use (cocaine, ketamine, ecstasy, methamphetamine, or ghb) in the past 90 days; * at least 1 instance of unprotected anal sex in the past 90 days; * biological male; * hiv-negative; * residential stability; * ability to communicate in written english. exclusion criteria: * unstable, serious psychiatric symptoms; * currently suicidal/homicidal; * evidence of gross cognitive impairment; * reports current enrollment in a drug or hiv related intervention or research study.

Keywords: sexual risk substance use hiv prevention intervention motivational enhancement therapy young men who have sex with men
comparison of an interscalene nerve block with or without stellate ganglion block for shoulder surgery

Conditions: Anesthesia, Regional

Summary: this study describes the difference of analgesic effect of levobupivacaine 0.5% administered through an interscalene nerve block with or without a stellate ganglion block. the length of the analgesic effect is our primary outcome parameter. half of the recruited patients will receive a stellate ganglion block and half of the patients won't.


Eligibility criteria:
inclusion criteria: * asa class 1 to 3 * need for shoulder surgery exclusion criteria: * mental retardation * allergy for local anesthetics * a medical reason as a contra-indication for nsaid use * diabetes mellitus * peripheral neuropathy * chronic analgetic use * chronic pain patients
biocurrent electrical stimulation for the treatment of dry armd

Conditions: Dry Macular Degeneration

Summary: this study evaluates the treatment of dry macular degeneration and the resulting change in vision with a very, very low current that is similar to what occurs in the body naturally. in phase 1, 16 participants will be treated, with half receiving treatment and half a sham (no treatment). after the treatment period of one week, those not treated will be treated. in phase 2, all participants will be treated.

the study will assess the effectiveness of transpalpebral micro-current electrical stimulation on improving the visual acuity in subjects with vision loss from dry macular degeneration. the biocurrent electrical stimulation will be applied by a device with the intended use of treating dry macular degeneration. the device delivers a micro-current, an electrical current in the one millionth of an ampere range, to the retina in frequencies changing in a pre-defined pattern from 5hz to 80hz during each spot (40 sec). the device also incorporates a voltage limiter (a maximum of 245 micro a is possible) and a current level indicator. 200 micro a will be used. very low electrical micro-current is delivered to the subject through the goggle probe.

Eligibility criteria:
inclusion criteria: * best-corrected visual acuity can be no better than 20/40 and no worse than 20/200 for each enrolled eye * confirmed diagnosis of dry md * vision loss attributable to dry md * subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent exclusion criteria: * any retinal pathology other than dry md * evidence or history of wet md * previous intravitreal injection * seizure disorders * dense cataract * eyelid pathology at the treatment sites * any prior electrical micro-stimulation treatment to the eyes * poor general health * active cancer * life expectancy less than 12 months * non-ambulatory * not considered suitable for participation for any other reason

Keywords: macular degeneration eye diseases retinal degeneration retinal diseases
ckd-581 + lenalidomide + dexamethasone in patients with previously treated multiple myeloma

Conditions: Myeloma, Multiple

Summary: this study is to determine the maximum tolerated dose(mtd) and recommened phase 2 dose(rp2d) based on dose limiting toxicity(dlt), and to evaluate safety and pharmacokinetics(pk) profile of a single agent ckd-581 injection in combination with lenalidomide and dexamethasone in patients with previously treated multiple myeloma.

this is an open label, dose escalation study. cohort of 3\~6 patients receive escalation doses of ckd-516 until the maximum tolerated dose(mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.

Eligibility criteria:
inclusion criteria: * must have received at least two prior lines of therapy and diagnosis of symptomatic multiple myeloma(imwg 2015) * eastern cooperative oncology group performance status ≤ 2 * life expectancy 12 weeks * must have the following laboratory values within 3 weeks prior to first dose of study drug * absolute neutrophil count(anc) ≥ 1,500 mm3 * platelet count(plt)≥ 100,000 mm3 * hb ≥ 9.0g/dl * ast(sgot) and alt(sgpt) ≤ 3 x upper limit of normal(unl) * serum bilirubin ≤ 1.5 x uln (but, gilbert syndrome ≤ 3 x unl) * creatinin clearance(crcl) ≤ 50ml/min * one more measureable disease following values * serum m-protein ≥ 1g/dl * urine m-protein ≥ 200mg/24hr * in that case serum m-protein, urine m-protein nonmeasurable and flc ratio abnormal, serum free light chain(flc) level ≥ 100mg/l(≥10mg/dl) * more than 24 weeks prior to last lenalidomide dose * must have signed the consent form exclusion criteria: * patients with cns disease * patients with clinically significant heart disease within 24weeks prior to first dose of study drug * patients with clinically significans abnormal ekg, echocardiography at screening * patients with patients with embolism within 24 weeks * patients with active hepatitis, hiv positive(exception, non active hepatitis) * peripheral neuropathy ≥ ctcae grade 2 within 2 weeks prior to first dose of study drug * patients with clinically significant disease * patients with a prior malignancy with in the last 3 years except adequately treated basal cell or squamous cell or skin cancer, in situ cervical cancer * patients who have received surgery, chemotherapy, radiation therapy or immunotherapy or any other investigational drugs ≤ 4 weeks prior to first dose of study drug and during treatment period * patients who can not anticoagulate * patients who have received dexamethasone \>10mg/day within 2week prior to first dose of study drug and during treatment period * women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control. male patients whose sexual partners are not using effective birth control. * patients with hypersensitive reaction of lenalidomide or dexamethasone
a phase 2b study of icosabutate in fatty liver disease

Conditions: Non Alcoholic Steatohepatitis (NASH)

Summary: a phase 2b study to evaluate the efficacy of different doses of nst-4016 on the resolution of nash without worsening of fibrosis

this is a 62 week (including screening and follow-up), multicenter, randomized, double blind, placebo-controlled, parallel group study in male and female patients with a histological diagnosis of nash. the study includes a screening period, double blind treatment period, and post-treatment follow up

Eligibility criteria:
inclusion criteria: * provides signed written informed consent and agrees to comply with the study protocol. * is a male or female aged 18 to 75 years, inclusive. * has a histological diagnosis of nash prior to study entry * has (nas) greater than or equal to 4, with a score of at least 1 in each component (steatosis, lobular inflammation, and ballooning), * has a fibrosis score f1 to f3, inclusive (f1 capped at 30%), * has a proton density fat fraction (pdff) greater than or equal to 10% on mri at screening exclusion criteria: * has a known history of alcohol abuse or daily heavy alcohol consumption * has had bariatric surgery within the past 5 years * has significant systemic or major illnesses other than liver disease * has a recent (within 6 months) history of cardiac dysrhythmias and/or cardiovascular disease * has uncontrolled arterial hypertension * positive for hep b, hepatitis c virus (hcv) or hcv polymerase chain reaction (pcr) * has type 1 diabetes mellitus * has diabetic ketoacidosis * has a history of liver decompensation
art: anal squamous cell carcinoma: investigation of functional imaging during chemoradiotherapy

Conditions: Anal Cancer

Summary: this is a single arm, single centre imaging study which will be offered to all consecutive, eligible patients receiving radical chemoradiation therapy (crt) for anal cancer within oxford university hospitals. investigations * dynamic contrast enhanced magnetic resonance imaging (dce mri) * diffusion weighted magnetic resonance imaging (dwi mri) * mri scan designed to measure the t1 or produce t1-weighed images (t1 mri) * mri scan designed to measure the t2\* or produce t2\*-weighed images (t2\* mri) * perfusion computed tomography (pct) * fludeoxyglucose positron emission tomography (fdg pet/ct) study design: observational target population: patients undergoing radical crt for anal cancer in oxford university hospitals national health service (nhs) trust. duration on study: patients should be on study for a maximum of 5 months. patient care post-trial: follow up as per local standard. no. of study site(s): single centre, united kingdon (uk) end of study: last patient, last assessment of response. patients should be on study for a maximum of 5 months.


Eligibility criteria:
inclusion criteria: * histologically confirmed invasive primary squamous carcinoma of the anus. * patients must be fit and scheduled to receive radical crt with curative intent. * any stage tumor 2-node 0 (t2n0) * male or female, age 18 years+. * the patient is willing and able to comply with the images and protocol for the duration of the study. * written (signed and dated) informed consent. exclusion criteria: * pregnant or breast-feeding women or women of childbearing potential unless effective methods of contraception are used. * previous pelvic radiotherapy * patients with a pacemaker or any other implanted metal which would preclude mri scan. * patients with a prosthetic hip. * patients receiving radiotherapy with palliative intent. * active medical or psychological illness that would render the patient unsuitable for the additional imaging proposed in this study, at the discretion of the investigator additional criteria for optional oxygen breathing procedure: * patients with chronic obstructive pulmonary disease * any patient not felt to be suitable for supplementary oxygen as considered by an appropriately trained clinician

Keywords: imaging chemoradiotherapy
effectiveness of smecta in the treatment of acute diarrhoea in children

Conditions: Diarrhoea

Summary: the purpose of this study is to evaluate the effectiveness of smecta at decreasing stool weight, when compared to placebo, in the treatment of acute diarrhoea in children.


Eligibility criteria:
inclusion criteria: * male * acute watery diarrhoea defined as at least 3 watery stools per 24 hours * duration of watery diarrhoea of less than 72 hours and with at least one watery stool during the last 12 hours * dehydration signs requiring oral rehydration according to current who guidelines exclusion criteria: * severe dehydration that needs iv therapy * presence of gross blood in stools * fever \> 39 degrees celsius * current treatment by an antidiarrheal medication
antaitavir hasophate capsules combined with yiqibuvir tablets in treatment adult patients with chronic hepatitis c

Conditions: Chronic HCV Infection

Summary: the safety, tolerability and antiviral activity of antaitavir hasophate in combination with yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis c virus (hcv) infection

phase ii: exploring the efficacy and safety of different doses of antaitavir hasophate combined with fixed-dose yiqibuvir in the treatment of adult patients with chronic hepatitis c for 12 weeks, providing a basis for the design and implementation of phase iii clinical trials. phase iii: confirmation of the efficacy and safety of antaitavir hasophate combined with yiqibuvir in the treatment of adult patients with chronic hepatitis c for 12 weeks, providing a sufficient basis for drug registration and clinical use.

Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent; 2. male or female, age≥18 years; 3. body mass index (bmi)≥18.0 and≤32.0 kg/m2, and weight≥40 kg; 4. serological detection of anti-hcv antibodies was positive at screening; 5. hcv rna≥1×104 iu/ml at screening; 6. hcv genotype 1\~6, mixed genotype or indeterminate assessed at screening by the central laboratory. exclusion criteria: 1. clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage); 2. chronic liver disease of a non-hcv etiology (including but not limited to hemochromatosis, wilson's disease,alfa-1 antitrypsin deficiency); 3. significant cardiac disease(including but not limited to myocardial infarction, bradycardia) ; 4. psychiatric illness or psychological disease or relevant medical history; 5. solid organ transplantation; 6. subjects have any other medical disorder that may interfere with subjects treatment, assessment or compliance with the protocol.
expression of vegf-c and vegf-cr in oral cancers and premalignant lesions

Conditions: Oral Cancer

Summary: the role of vascular endothelial growth factor-c (vegf-c) and its receptors induced lymphangiogenesis and host inflammatory responses on the carcinogenesis of oral cancers and premalignant lesions

the role of vascular endothelial growth factor-c (vegf-c) and its receptors induced lymphangiogenesis and host inflammatory responses on the carcinogenesis of oral cancers and premalignant lesions

Eligibility criteria:
inclusion criteria: * oral cancer and oral precancer specimens exclusion criteria: * other diseases

Keywords: vascular endothelial growth factor-c vegf-cr lymphangiogenesis host inflammatory responses oral carcinogenesis oral cancers oral premalignant lesions
synchronous video (telemedicine) consulation in the prehospital setting

Conditions: Emergencies; Prehospital; Telemedicine; Telehealth

Summary: the study team aims to test connectivity metrics and follow patient outcomes using a new, innovative synchronous video technology in the prehospital setting in three distinct areas: 1. - 911 calls 2. - pediatric critical care transport currently, paramedics and pediatric transport teams seek advice from physicians using a telephone. this project replaces the phone with video consultation where the physicians can directly interact with patients, paramedics and transport teams when care advice is needed.


Eligibility criteria:
inclusion criteria: * cardiac arrest * hemodynamically unstable trauma patients requiring resuscitation and airway management * trauma patients with altered mentation requiring airway management * acute stroke patients * medical patients that refuse transport for medical evaluation pediatric intensive care telemedicine program * complex clinical situations where paramedic teams need immediate management guidance * critically ill pediatric patients requiring evaluation/stabilization for interfacility transport * pediatric patients requiring intervention for respiratory failure * pediatric patients with ongoing seizures and/or neurological abnormalities * hemodynamically unstable patients * complex clinical situations requiring medical control guidance exclusion criteria: • all other patients not list above
eeg-based sedation protocol for patients on mechanical ventilation due to sars-cov-2 pneumonia

Conditions: Sedation Complication; Covid19

Summary: deep sedation in patients with covid-19 may be challenging in many aspects. the use of an eeg-based protocol to guide deep sedation may be useful in this particular population, considering their unusually high sedation requirements. in the present trial, we aim to evaluate an eeg-based protocol to guide deep sedation in patients with covid19, using to eeg derived parameters that are displayed in the bis monitor: suppression rate and spectral edge frequency. the protocol is designed to both minimize the suppression rate along with maintaining a spectral edge frequency over 10 hz. the use of this protocol may reduce the amount of sedatives administered and, therefore, diminish the time needed for the weaning process.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * covid-19 patient requiring mechanical ventilation exclusion criteria: * contraindication to receive propofol or fentanyl * chronic liver disease child c * end-stage kidney chronic disease